Supplementary Table S1 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Pinkal Desai(NewYork–Presbyterian Hospital), James S. Blachly(The Ohio State University Wexner Medical Center), Ian W. Flinn(Tennessee Oncology), Jamal Saeh(AstraZeneca (Brazil)), Marcio Andrade‐Campos(AstraZeneca (United Kingdom)), Susan O’Brien(University of California, Irvine), Margaret Wey(The University of Texas at San Antonio Health Science Center), Javid J. Moslehi(Cardiovascular Institute of the South), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Sagar Lonial(Emory University), Shringi Sharma(AstraZeneca (United Kingdom)), Amanda F. Cashen(Washington University in St. Louis), Mary Liu(AstraZeneca (United Kingdom)), Damilola Olabode(AstraZeneca (United Kingdom)), Neha Korde(United States Fish and Wildlife Service), Hong Chen(AstraZeneca (United Kingdom)), Patricia Cheung(AstraZeneca (United Kingdom)), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Firasath Ali Syed(AstraZeneca (United Kingdom)), Manali Kamdar(University of Colorado Cancer Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k